Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel,…
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
March 03, 2025 09:27 ET | Source: Pliant Therapeutics, Inc. SOUTH SAN…
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025 12:45 ET | Source: Celldex Therapeutics, Inc. - Greatly…
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET…
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)
February 18, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
fullthrottle.ai Appoints Ken Kennedy as CEO, Accelerating Next Phase of Growth
PHILADELPHIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- FullThrottle Technologies, LLC, a pioneering…
Inaugural Public Art Abu Dhabi Biennial launches second phase with new artwork unveilings across the emirate
The Public Art Abu Dhabi Biennial runs until 30 April 2025 across…
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
February 11, 2025 17:30 ET | Source: AnaptysBio, Inc. SAN DIEGO, Feb.…
EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior…